Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims This study compared the effect of insulin detemir on glycaemic control (HbA 1c, fasting plasma glucose and variability thereof) with that of Neutral Protamine Hagedorn human isophane (NPH) insulin, both combined with insulin aspart, in children with Type 1 diabetes mellitus, and compared the safety of these treatments. Methods In this 26‐week, open‐label, randomized (2 : 1), parallel‐group study, 347 (140 prepubertal and 207 pubertal) children with Type 1 diabetes, aged 6–17 years, received insulin detemir (n = 232) or NPH insulin (n = 115) once or twice daily, according to the prestudy regimen, plus premeal insulin aspart. Results The mean HbA 1c decreased by ∼0.8% with both treatments. After 26 weeks, the mean difference in HbA 1c was 0.1% (95% confidence interval −0.1, 0.3) (insulin detemir 8.0%, NPH insulin 7.9%). Within‐subject variation in self‐measured fasting plasma glucose was significantly lower with insulin detemir than with NPH insulin (SD 3.3 vs. 4.3, P < 0.001), as was mean fasting plasma glucose (8.4 vs. 9.6 mmol/l, P = 0.022). The risk of nocturnal hypoglycaemia (22.00–07.00 h) was 26% lower with insulin detemir (P = 0.041) and the risk of 24‐h hypoglycaemia was similar with the two treatments (P = 0.351). The mean body mass index (BMI) Z‐score was lower with insulin detemir (P < 0.001). Conclusions Basal‐bolus treatment with insulin detemir or NPH insulin and premeal insulin aspart in children and adolescents with Type 1 diabetes mellitus improved HbA 1c to a similar degree. The lower and more predictable fasting plasma glucose, lower risk of nocturnal hypoglycaemia and lower BMI observed with insulin detemir are clinically significant advantages compared with NPH insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Hypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
WANG, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)90816-y · Cited by 446
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Davis, E. A., Keating, B., Byrne, G. C., Russell, M., & Jones, T. W. (1997) · Diabetes Care · doi:10.2337/diacare.20.1.22 · Cited by 273
Cited by
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
“It should also be considered that in trials performed on type 1 diabetic patients, in combination with prandial short-acting insulin, determir does not improve HbA1c in comparison with NPH [20–24], whereas glargine is either equally effective [25–28] or superior [29,30] to NPH insulin.”
ResultBlonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Insulin analogues: an example of applied medical science
Sheldon, B., Russell‐Jones, D., & Wright, J. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01015.x · Cited by 69
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194801 · Cited by 41
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Metadata
- Authors
- Robertson, K. J., Schoenle, E., Gucev, Z., Mordhorst, L., Gall, M. ‐., & Ludvigsson, J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 24
- Issue
- 1
- Pages
- 27-34
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2029491585
- Cited by
- 149
- References
- 13
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2007.02024.x
- The paper
- Robertson, K. J., Schoenle, E., Gucev, Z., Mordhorst, L., Gall, M. ‐., & Ludvigsson, J. (2007). Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2007.02024.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.